The DOI matches its Crossref record.
CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine
Abstract
OBJECTIVE: To determine the extent to which lymphocytes, particularly those with the CD4 surface antigen, are a surrogate marker for the development of the acquired immunodeficiency syndrome (AIDS) in persons with asymptomatic human immunodeficiency virus (HIV) infection. DESIGN: Analysis of data from the AIDS Clinical Trials Group Protocol 019, a placebo-controlled, double-blind, randomized trial. SETTING: University-based referral centers. PATIENTS: Asymptomatic HIV-infected patients with 500 or fewer CD4+ cells/mm3 at baseline who were given placebo (350 patients) or one of two daily doses of zidovudine (725 patients). MEASUREMENTS: Baseline and interim measurements of CD4+ and other leukocytes were assessed. Patients were followed for progression to AIDS. RESULTS: Patients' lymphocyte levels were correlated with progression to AIDS (P < 0.001; relative risk for each depletion of 50 CD4+ cells/mm3, 1.75; 95% CI, 1.53 to 2.01); however, only a small portion (0% to 37%) of the effect of zidovudine on this progression was statistically explained by its effect on CD4+ lymphocyte levels. A substantial portion of zidovudine's effect on delaying progression to AIDS that was independent of the levels of these markers occurred within the first 16 weeks of therapy. In patients who had not progressed to AIDS by week 16, most of the subsequent zidovudine effect in reducing the risk for progression could be explained by its effect on net CD4+ percent (percentage of CD4+ lymphocytes among all leukocytes) for the first 16 weeks of therapy. CONCLUSION: Levels of CD4+ lymphocytes are an incomplete surrogate marker for progression to AIDS, and the association is especially weak during the first 16 weeks of zidovudine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS
O'Brien, W. A., Hartigan, P. M., Martin, D., Esinhart, J., Hill, A., Benoit, S., Rubin, M., Simberkoff, M. S., & Hamilton, J. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602153340703 · Cited by 720
The validation of surrogate endpoints in meta-analyses of randomized experiments
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 624
ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER
LIN, D. Y., FLEMING, T. R., & DE GRUTTOLA, V. (1997) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1 · Cited by 520
Metadata
- Authors
- Choi, S., Lagakos, S. W., Schooley, R. T., & Volberding, P. A.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1993-05-01
- Volume
- 118
- Issue
- 9
- Pages
- 674-680
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1983112408
- Cited by
- 190
- References
- 0
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine. https://app.cochat.ai/papers/10.7326/0003-4819-118-9-199305010-00003
- The paper
- Choi, S., Lagakos, S. W., Schooley, R. T., & Volberding, P. A. (1993). CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-118-9-199305010-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.